Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVAX: Survivin peptide vaccine (Survivac) plus IMP321 in prostate cancer with biochemical failure
2009-017798-39Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maveropepimut-S and eftilagimod alpha in prostate cancer (PCa), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Incidence of grade ≥2 treatment-related adverse events and injection site reactions. Started Jun 2010; status: completed.
02
Drugs
maveropepimut-Seftilagimod alpha
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-017798-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017798-39.